Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75487
UPID:
GPC4_HUMAN
Alternative names:
K-glypican
Alternative UPACC:
O75487; B2R6J7; B4E2C0; Q6ZMA6; Q96L43; Q9NU08; Q9UJN1; Q9UPD9
Background:
Glypican-4, also known as K-glypican, is a cell surface proteoglycan with heparan sulfate chains. It plays a crucial role in the development of kidney tubules and the central nervous system, suggesting its involvement in cellular signaling and tissue organization.
Therapeutic significance:
Glypican-4's association with Keipert syndrome, a genetic disorder marked by craniofacial, digital abnormalities, and potential cognitive impairment, underscores its clinical importance. Understanding Glypican-4's function could lead to novel therapeutic strategies for managing Keipert syndrome and related conditions.